A Study of MEDI9197 in Participants with Solid Tumors or CTCL and in Combination with Durvalumab and/or Palliative Radiation in Participants with Solid Tumors

Study identifier:D6410C00001

ClinicalTrials.gov identifier:NCT02556463

EudraCT identifier:2015-005783-41

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and/or Palliative Radiation in Subjects with Solid Tumors

Medical condition

Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI9197, Durvalumab

Sex

All

Actual Enrollment

53

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 04 Nov 2015
Primary Completion Date: 26 Oct 2018
Study Completion Date: 26 Oct 2018

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2019 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria